{"cluster": 20, "subcluster": 19, "abstract_summ": " Global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories . Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate . In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies . In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons ."}